Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Vanessa Cravatta

Nurse Practitioner, Pediatrics Winter Park, FL Nurse Practitioner

NPI 1205184900 CMS profile 10429063

2660 W Fairbanks Ave, Winter Park, FL 32789

Open in the dashboard

General payments

$5,769

240 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vanessa Cravatta of Winter Park, FL is reported in the CMS Open Payments database as having received $5,769 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,108 87
2024 General $1,468 60
2023 General $1,163 46
2022 General $793 35
2021 General $237 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vanessa Cravatta
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Vanessa Cravatta were reported at $2,108. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Vanessa Cravatta Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $237 $60 $23–$142 $132
2022 $793 $72 $27–$161 $149
2023 $1,163 $89 $35–$185 $160
2024 $1,468 $93 $34–$199 $164
2025 $2,108 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,180 38 payments
  2. Jazz Pharmaceuticals Inc. $916 34 payments
  3. Regeneron Healthcare Solutions, Inc. $638 29 payments
  4. Harmony Biosciences LLC $580 31 payments
  5. Genzyme Corporation $401 17 payments
  6. GlaxoSmithKline, LLC. $353 21 payments
  7. Amgen Inc. $271 6 payments
  8. Novartis Pharmaceuticals Corporation $230 11 payments
  9. Avadel CNS Pharmaceuticals, LLC $184 8 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $172 6 payments
  11. Other $843 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,669 239 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. XYWAV $916 34 payments
  2. TEZSPIRE Respiratory $724 16 payments
  3. FASENRA $690 20 payments
  4. DUPIXENT Immunology $401 17 payments
  5. DUPIXENT Inflammation And Immunology $357 16 payments
  6. NUCALA $353 21 payments
  7. WAKIX Narcolepsy $310 18 payments
  8. DUPIXENT Immunology And Inflammation $281 13 payments
  9. TEZSPIRE Inflammation $271 6 payments
  10. WAKIX Narcoplepsy $237 12 payments
  11. Other $1,515 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record